LSZ
Jump to navigation
Jump to search

LSZ, also known as Lysergic acid 2,4-dimethylazetidide, is a hallucinogenic drug and an analogue of LSD developed by the team led by David E. Nichols at Purdue University. While LSZ has subtly different effects than LSD, it appears to be slightly longer lasting and slightly more potent.
Dosage[edit | edit source]
Threshold | 80ug |
Light | 100-150μg |
Common | 150-300μg |
Strong | 300μg+ |
Duration[edit | edit source]
Onset | 90-120 minutes |
Duration | 7-10 hours |
After-effects | 1-24 hours. |
Effects[edit | edit source]
While LSZ has subtly different effects than LSD, with a slightly shorter duration while also having a longer comeup.
Harm Reduction[edit | edit source]
While widespread use of LSZ is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to LSD. Refer to LSD and Psychedelic Harm Reduction for more information.
Images[edit | edit source]
-
LSZ
Legal status[edit | edit source]
- USA: Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.